Heparinase III and uses thereof

Details Heparinase III and uses thereof Heparinase III and uses thereof

2005-03-22

2005-03-22

Prouty, Rebecca E. (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Lyase

C530S811000

Reexamination Certificate

active

06869789

ABSTRACT:
The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

REFERENCES:
patent: 4281108 (1981-07-01), Fussi
patent: 4341869 (1982-07-01), Langer, Jr. et al.
patent: 4373023 (1983-02-01), Langer et al.
patent: 4396762 (1983-08-01), Langer et al.
patent: 4443545 (1984-04-01), Langer, Jr. et al.
patent: 4551296 (1985-11-01), Kavesh et al.
patent: 4679555 (1987-07-01), Sackner
patent: 4745105 (1988-05-01), Griffin et al.
patent: 4757056 (1988-07-01), Van Gorp et al.
patent: 4830013 (1989-05-01), Maxwell
patent: 4928694 (1990-05-01), Maxwell
patent: 4942156 (1990-07-01), Foley et al.
patent: 4990502 (1991-02-01), Lormeau et al.
patent: 5010063 (1991-04-01), Piani et al.
patent: 5039529 (1991-08-01), Bergendal et al.
patent: 5106734 (1992-04-01), Nielsen
patent: 5152784 (1992-10-01), Tsilibary
patent: 5164378 (1992-11-01), Conti et al.
patent: 5169772 (1992-12-01), Zimmerman et al.
patent: 5204323 (1993-04-01), Findlay et al.
patent: 5252339 (1993-10-01), Cristofori et al.
patent: 5262325 (1993-11-01), Zimmermann et al.
patent: 5290695 (1994-03-01), Morikawa et al.
patent: 5338677 (1994-08-01), Zimmermann et al.
patent: 5389539 (1995-02-01), Sasisekharan et al.
patent: 5453171 (1995-09-01), Ma et al.
patent: 5474987 (1995-12-01), Cohen et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5569366 (1996-10-01), Chen et al.
patent: 5569600 (1996-10-01), Sasisekharan et al.
patent: 5576304 (1996-11-01), Kakkar et al.
patent: 5599801 (1997-02-01), Branellec et al.
patent: 5607859 (1997-03-01), Biemann et al.
patent: 5618917 (1997-04-01), Toback et al.
patent: 5619421 (1997-04-01), Venkataraman et al.
patent: 5681733 (1997-10-01), Su et al.
patent: 5687090 (1997-11-01), Chen et al.
patent: 5714376 (1998-02-01), Sasisekharan et al.
patent: 5744515 (1998-04-01), Clapper
patent: 5752019 (1998-05-01), Rigoutsos et al.
patent: 5753445 (1998-05-01), Fillit et al.
patent: 5759767 (1998-06-01), Lakowicz et al.
patent: 5763427 (1998-06-01), Weitz et al.
patent: 5767269 (1998-06-01), Hirsh et al.
patent: 5776434 (1998-07-01), Purewal et al.
patent: 5795875 (1998-08-01), Holme et al.
patent: 5808021 (1998-09-01), Holme et al.
patent: 5824299 (1998-10-01), Luster et al.
patent: 5830726 (1998-11-01), Sasisekharan et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5856928 (1999-01-01), Yan
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 5919693 (1999-07-01), Su et al.
patent: 5922358 (1999-07-01), Doutremepuich et al.
patent: 5952653 (1999-09-01), Covey et al.
patent: 5968822 (1999-10-01), Pecker et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5990097 (1999-11-01), Kennedy
patent: 5993846 (1999-11-01), Friedman et al.
patent: 5997863 (1999-12-01), Zimmermann et al.
patent: 6013628 (2000-01-01), Skubitz et al.
patent: 6116237 (2000-09-01), Schultz et al.
patent: 6136295 (2000-10-01), Edwards et al.
patent: 6190875 (2001-02-01), Ben-Artzi et al.
patent: 6217863 (2001-04-01), Godavarti et al.
patent: 6268146 (2001-07-01), Shultz et al.
patent: 6291439 (2001-09-01), Klock
patent: 6309853 (2001-10-01), Friedman et al.
patent: 6333051 (2001-12-01), Kabanov et al.
patent: 6597996 (2003-07-01), Venkataraman et al.
patent: 0 140 781 (1985-05-01), None
patent: 0 114 589 (1987-09-01), None
patent: 0 244 236 (1987-11-01), None
patent: 0 394 971 (1990-10-01), None
patent: 0 433 225 (1991-06-01), None
patent: 0 342 215 (1993-08-01), None
patent: 0 557 887 (1993-09-01), None
patent: WO 9201003 (1992-01-01), None
patent: WO 9305167 (1993-03-01), None
patent: WO 9308289 (1993-04-01), None
patent: WO 9310450 (1993-05-01), None
patent: WO 9315406 (1993-08-01), None
patent: WO 9319096 (1993-09-01), None
patent: WO 9319734 (1993-10-01), None
patent: WO 9412618 (1994-06-01), None
patent: WO 9421689 (1994-09-01), None
patent: WO 9513830 (1995-05-01), None
patent: WO 9534635 (1995-12-01), None
patent: WO 9601648 (1996-01-01), None
patent: WO 9632149 (1996-10-01), None
patent: WO 9706783 (1997-02-01), None
patent: WO 9711684 (1997-04-01), None
patent: WO 9716556 (1997-05-01), None
patent: WO 9735562 (1997-10-01), None
patent: WO 9804902 (1998-02-01), None
patent: WO 9831346 (1998-07-01), None
patent: WO 0012726 (2000-03-01), None
patent: WO 0065521 (2000-11-01), None
Wishart et al, A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J Biol Chem. Nov. 10, 1995;270(45):26782-5.*
Witkowski et al, Conversion of a beta-ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with glutamine. Biochemistry. Sep. 7, 1999;38(36):11643-50.*
DL Lohse and RJ Linhardt Purification and characterization of heparin lyases fromFlavobacterium heparinumJ. Biol. Chem. 1992 267:24347-24355.*
Alderman, C.P. et al., “Continuous Subcutaneous Heparin Infusion for Treatment of Trousseau's Syndrome”,The Annals of Pharmacotherapy, Jul./Aug. 1995, pp. 710-713, vol. 29.
Baumann, U. et al., “Three-dimensional structure of the alkaline protease ofPseudomonas aeruginosa: a two-domain protein with a calcium binding parallel beta roll motif”,The EMBO Journal, 1993, pp. 3357-3364, vol. 12, No. 9.
Bernstein, H. et al., “Immobilized Heparin Lyase System for Blood Deheparinization”,Methods in Enzymology, 1988, pp. 515-529, vol. 137, Academic Press, Inc.
Cardin, A.D. et al., “Molecular Modeling of Protein-Glycosaminglycan Interactions”,Arteriosclerosis, Jan./Feb. 1989, pp. 21-32, vol. 9, No. 1.
Cohen, F.E., “The Parallel β Helix of Pectate Lyase C: Something to Sneeze At”,Science, Jun. 4, 1993, pp. 1444-1445, vol. 260.
Comfort, A.R. et al., “Immobilized Enzyme Cellulose Hollow Fibers: III. Physical Properties and In Vitro Biocompatibility”,Biotechnology and Bioengineering, 1989, pp. 1383-1390, vol. 34, John Wiley & Sons, Inc.
Enriquez-Harris, P. et al., “Growth factors and the extracellular matrix”,Meeting Report, Trends in Cell Biology, 1994, 2 Pages.
Ernst, S. et al., “Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase I”,Proc. Natl. Acad. Sci. USA, Apr. 1998, pp. 4182-4187, vol. 95, Biochemistry.
Feingold, D.S. et al., “Conformational aspects of the reaction mechanisms of polysaccharide lyases and epimerases”,FEB Letters, Nov. 1987, pp. 207-211, vol. 223, No. 2, Elsevier Science Publishers B.V.
Franklin, M.J. et al., “Pseudomonas aeruginosaAlgG is a Polymer Level Alginate C5-Mannuronan Epimerase”,Journal of Bacteriology, Apr. 1994, pp. 1821-1830, vol. 176, No. 7, American Society for Microbiology.
Gacesa, P., “HypothesisAlginate-modifying enzymes, A proposed unified mechanism of action for the lyases and epimerases”,FEB Letters, Feb. 1987, pp. 199-202, vol. 212, No. 2, Elsevier Science Publishers B.V.
Godavarti, R. et al., “Heparinase I fromFlavobacterium heparinum. Identification of a Critical Histidine Residue Essential for Catalysis as Probed by Chemical Modification and Site-Directed Mutagenesis”,Biochemistry, 1996, pp. 6846-6852, vol. 35, No. 21, American Chemical Society.
Godavarti, R. et al., “Heparinase III forFlavobacterium heparinum: cloning and recombinant expression inEscherichia coli”, Biochem. Biophys. Res. Commun., Aug. 23, 1996, pp. 751-758, vol. 225, No. 3, Academic Press, Inc.
Godavarti, R. et al., “A comparative analysis of the primary sequences and characteristics of heparinases I, II, and III

Affiliated with

Also associated with

Rating

Heparinase III and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heparinase III and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heparinase III and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3455752